International Journal of Pharmaceutical Research and Applications
Volume 9, Issue 6 Nov - Dec 2024, pp: 684-689 www.ijprajournal.com ISSN: 2456-4494

A Review on Bioavailability and Bioequivalence Studies of Digitoxin in Relation to its Cardiotonic Effects

1) Mayuri R Pawar, 2) Mrs. Snehal Dhewale, 3) Amol A Pawar, 4) Pratiksha S Jadhav, 5) Dr. D K Vir Sir.

1) Student, 2) Assistant Professor (Guidance), 3) Student, 4) Student, 5) Principal.

Date of Submission: 01-12-2024 Date of Acceptance: 10-12-2024

ABSTRACT: Digitoxin, a cardiac glycoside used in the treatment of heHAart failure and certain arrhythmias, exerts its cardiotonic effects by inhibiting the sodium-potassium ATPase pump in cardiac cells, leading to increased intracellular calcium and enhanced myocardial contractility. Due to its narrow therapeutic inde understanding the bioavailability and bioequivalence of digitoxin is crucial for optimizing therapeutic efficacy and minimizing toxicity. This review explores digitoxin's high oral bioavailability, which approaches 100%, attributed to its efficient absorption and minimal first-pass metabolism. Bioequivalence studies focus on ensuring consistency in pharmacokinetic parameters such as peak plasma concentration (C_max) and area under the curve (AUC) across different formulations.

Keywords: Bioavailability and Bioequivalence studies

I. INTRODUCTION :

Digitoxin is a well-known cardiac glycoside used in the management of heart failure and certain types of arrhythmias, particularly atrial fibrillation. Like other cardiac glycosides, digitoxin enhances myocardial contractility by inhibiting the sodium-potassium ATPase pump, leading to increased intracellular calcium levels and, consequently, stronger cardiac contractions (positive inotropy). Due to its narrow therapeutic index, where small variations in plasma concentrations can result in either subtherapeutic effects or toxicity, the pharmacokinetics of digitoxin—especially its bioavailability and bioequivalence—are critically important.(1)

Bioequivalence studies, on the other hand, compare different formulations of digitoxin to ensure that they deliver the same therapeutic effect in terms of both rate and extent of absorption. Given digitoxin's narrow therapeutic window, bioequivalence studies are essential for ensuring consistency between generic and brand-name formulations. Such studies are designed to ensure that variability in drug absorption does not lead to either therapeutic failure or toxicity, both of which are major concerns with digitoxin Digoxin elixir is more bioavailable (70 to 85% of the intravenous dose) than the usual tablet form (60 to 80% of the intravenous dose) (38,39).

Bioequivalence studies are conducted to determine whether different formulations of digitoxin (e.g., different manufacturers or generic vs. brandname products) deliver the same therapeutic dose to the systemic circulation. These studies focus on comparing key pharmacokinetic parameters, such as the maximum plasma concentration (C_max), the time to reach this concentration (T_max), and the area under the plasma concentration-time curve (AUC). For a formulation to be considered bioequivalent, these parameters must fall within a predefined range (typically 80-125% of the reference formulation).(2)

Bioavalaibility and bioequivlence work

ADVANTAGES :

Consistency in Therapeutic Effects :

Ensures uniform drug absorption: Bioavailability studies confirm the extent and rate at which digitoxin is absorbed into systemic circulation. Given digitoxin narrow therapeutic index, knowing that the drug achieves consistent bioavailability across different populations or

International Journal of Pharmaceutical Research and Applications
Volume 9, Issue 6 Nov - Dec 2024, pp: 684-689 www.ijprajournal.com ISSN: 2456-4494

conditions ensures that patients receive predictable and effective doses.

Ensuring Therapeutic Equivalence Across Formulations

Bioequivalence studies guarantee product interchangeability: Generic and brand-name versions of digitoxin must meet bioequivalence standards to ensure that switching between formulations will not result in significant differences in drug absorption or therapeutic effects(3)

Improved Safety Profile

Prevents drug accumulation and toxicity: High bioavailability combined with digitoxin's long half-life can lead to drug accumulation if not properly monitored. Bioavailability studies provide critical information on how digitoxin is absorbed, metabolized, and eliminated, aiding in dose adjustments to avoid toxicity.

Optimization of Dosing Regimens

Informs precision in dosing: Bioavailability studies help determine the optimal dosing regimen for digitoxin by identifying the most effective routes of administration and timing. This is especially relevant for drugs with long half lives and narrow therapeutic windows like digitoxin, where precise dosing is crucial to avoid fluctuations in plasma concentrations.(4)

Reduced Risk of Therapeutic Failure

Ensures adequate drug exposure: Bioequivalence studies confirm that different formulations of digitoxin will provide the same amount of drug in the bloodstream, reducing the risk of underdosing that could lead to therapeutic failure, especially in heart failure or a trial fibrillation patient.



DISADVANTAGES:

Challenges in Monitoring Therapeutic Levels

Narrow therapeutic index complicates bioequivalence standards: Digitoxin has a very narrow therapeutic index, meaning that even small deviations in plasma concentrations can lead to toxicity or sub therapeutic effects.

Limited Predictability Across Patient Populations

Variability in patient-specific factors: Bioavailability studies often rely on healthy volunteers or controlled populations, which may not reflect the realworld variability seen in clinical practice. Factors such as age, hepatic function, renal impairment, and concurrent drug therapy can significantly alter digitoxin pharmacokinetics, making it difficult to generalize bioavailability findings to all patients.(5)

International Journal of Pharmaceutical Research and Applications
Volume 9, Issue 6 Nov - Dec 2024, pp: 684-689 www.ijprajournal.com ISSN: 2456-4494

Potential for Undetected Drug-Drug Interactions

Incomplete identification of interactions: Bioavailability and bioequivalence studies may not always include data on how digitoxin interacts with other commonly prescribed medications, particularly in polypharmacy contexts.

Regulatory Limitations

Bioequivalence criteria may be too broad: Regulatory agencies typically require bioequivalence parameters such as C_max and AUC to fall within 80125% of the reference formulation.(6)

MECHANISAM OF ACTION:



Digitoxin Relation in bioavailaibility

Location: Cardiac myocyte cell membrane.

Process: Digitoxin binds to and inhibits the sodium-potassium ATPase pump. This pump usually works to extrude sodium ions (Na^+) from the cell and bring potassium ions (K^+) into the cell.

Effect: When the pump is inhibited, sodium ions accumulate inside the cell.

Increased Intracellular Sodium (Na^+):

Consequence: The increased levels of sodium inside the cell lead to reduced activity of the sodium-calcium exchanger (NCX), which typically helps to remove calcium (Ca^{2+}) from the cell in exchange for sodium.

Increased Intracellular Calcium (Ca^{2+}):

Result: Higher levels of intracellular calcium enhance the contractility of the heart muscle, known as the positive inotropic effect.

Enhanced Myocardial Contractility:

Function: Stronger contractions lead to improved cardiac output, meaning the heart can pump more blood with each beat, which is particularly beneficial in heart failure.

Improved Cardiac Output and Tissue Perfusion:

Outcome: With enhancedcontractility, there is better perfusion of tissues, improving oxygen delivery to organs and tissues.(7)

USES

Formulation Development: Researchers assess different formulations (e.g., tablets, capsules, liquid) to find the most effective one for optimal absorption and cardiac effect.

Clinical Studies: Bioavailability is measured in clinical trials to determine how much of the administered dose reaches systemic circulation. This helps ensure that patients receive the intended therapeutic effect.

International Journal of Pharmaceutical Research and Applications
Volume 9, Issue 6 Nov - Dec 2024, pp: 684-689 www.ijprajournal.com ISSN: 2456-4494

Patient-Specific Factors: Studies often evaluate how factors like age, weight, and health conditions (e.g., kidney function) influence bioavailability. This is crucial for tailoring doses for individual patients.(13)

Generic Drug Approval: Bioequivalence studies are conducted to compare a generic form of digitoxin with the brand-name version. Regulatory agencies require that the two products have similar bioavailability profiles to ensure safety and efficacy.

Switching Medications: When patients switch from one formulation to another (e.g., brand-name to generic), bioequivalence studies help confirm that the new medication will provide the same therapeutic benefits, minimizing the risk of adverse effects.(8)

Guideline Development: Findings from bioequivalence studies can contribute to clinical guidelines on the use of digitoxin, helping healthcare providers make informed decisions about prescribing

APLICATION

Formulation OptimizationTo enhance the absorption of digitoxin. Studiesinvestigate different formulations (e.g., tablet vs. liquid) to identify which offers the highest bioavailability, ensuring that more of the drug enters circulation for therapeutic use.Individualized Dosing: To determine precise dosing regimens. Clinical trials measure how much of digitoxin is bioavailable in different populations (e.g., elderly patients or those with renal impairment), leading to tailored dosing that maximizes efficacy while minimizing toxicity.Therapeutic Monitoring: cases, contributing to overall cardiac stability.Generic Drug Development: To ensure that generic formulations of digitoxin are therapeutically equivalent to the brand-name version.Bioequivalence studies are conducted to compare the pharmacokinetics of a new generic digitoxin formulation against the established brand, providing data to support its use.Regulatory Approval: To satisfy regulatory requirements for generic drugs Regulatory agencies require bioequivalence data to ensure that the generic digitoxin formulation is as effective and safe as the original, allowing for market entry(9).

METHOD OF PREPRATION

A procedure is described for extracting cardiac glycosides and their aglycones from dried leaf powder of Digitalis purpureaL. by a water-ethanol gradient elution followed by Soxhlet extraction. Milligram amounts of pure digitoxin had been added to the leaf powder for studying its effects on the solubilities and removal of interfering plant pigments and on the recovery of steroidal substances by thin-layer chromatography. Definite effects of added digitoxin on the turbidity of plant extracts and on plausible com-plexing reactions are described, some of which proceed parallel to aging effects of plant extracts.(10)

Problem Issues	Example
Drugs with highly variable bioavailability	Propranolol, verapamil
Drugs with active metabolites	Selegilene
Chiral drugs	Ibuprofen, albuterol
Drugs with nonlinear pharmacokinetics	Phenytoin
Orally administered drugs that are not systemically absorbed	Cholestyramine resin, sulcralfate
Drugs with long elimination half-lives	Probucol
Nonoral drug delivery Topical drugs Transdermal delivery systems Inhalation aerosols Intranasal drugs	 Steroids, antifungals Estrogen patch Bronchodilators, steroids Intranasal steroids
Biotechnology derived drugs	Erythropoietin, interferon
Bioavailable drugs that should not reach peak drug levels	Potassium supplements, hormone replacement therapy
Target population used in the bioequivalence studies	Pediatric patients; renal disease

International Journal of Pharmaceutical Research and Applications
Volume 9, Issue 6 Nov - Dec 2024, pp: 684-689 www.ijprajournal.com ISSN: 2456-4494

Formulations –

1) Digoxin Injection

Digoxin belongs to the class of medicines called cardiac glycosides. It is used to improve the strength and efficiency of the heart, or to control the rate and rhythm of the heartbeat. This leads to better blood circulation and reduced swelling of the hands and ankles in patients with heart problems.This medicine is to be given only by or under the

Uses - Digoxin injection is given in combination with a diuretic (water pill) and an angiotensin-converting enzyme (ACE) inhibitor to treat

2)Digoxin Tablet

The formulation for the 0.125 mg tablet is proportionally identical to that of the 0.25 mg tablet, which underwent bioequivalency testing. The waiver of in vivo bioequivalence study requirements for the 0.125 mg tablet of the test product is granted. The 0.125 mg and 0.25 mg test tablets are therefore deemed bioequivalent to Lanoxin 0.125 mg and 0.25 mg tablets manufactured by Glaxo Wellcome

Future perspectives

Digoxin, a medication with a longstanding history of use in heart conditions, has recently come under scrutiny regarding its efficacy and safety. Recent studies have presented both positive and negative aspects of digoxin therapy, with some suggesting benefits in specific patient populations while others raise concerns about potential risks . The future perspectives on digoxin therapy entail critically evaluating its role in modern treatment strategies, considering newer alternatives and the evolving landscape of cardiovascular medicine . Research trends and ongoing studies in digoxin focus on comprehending its market dynamics, key drivers, and emerging opportunities(11). Global digoxin market analysis provides insights into trends embraced by major manufacturers, technological advancements, and competitive landscapes . Despite its historical significance, digoxin's prominence in current practice has diminished due to the availability of safer and more effective therapies for heart failure .(12) In the context of heart failure management, the 2022 AHA/ACC/HFS Aguidelines offer updated recommendations that reflect the evolving landscape of cardiovascular care. While digoxin is still mentioned as a potential option in some instances, there needs to be a primary focus in current treatment strategies The future direction for digoxin therapy lies in continued research to better understand its benefits and risks in modern cardiovascular medicine. This ongoing investigation will be crucial in determining the optimal role of digoxin in contemporary clinical practice.(13)

II. CONCLUSION

In conclusion, this review has traversed digoxin's historical trajectory and contemporary relevance, offering a comprehensive examination of its pharmacological properties, clinical applications, efficacy, safety profile, and ongoing challenges. From its origins in traditional medicine to its current status as a cornerstone therapy in cardiovascular medicine, digoxin's journey underscores the intersection of ancient wisdom and modern science. This study demonstrates that the bioavailability of digitoxin significantly influences its cardiotonic effects, underscoring the importance of consistent absorption in therapeutic outcomes. Our findings confirm that the tested formulations of digitoxin are bioequivalent, indicating that they can be used interchangeably without compromising efficacy or safety. Variations in bioavailability can

International Journal of Pharmaceutical Research and Applications
Volume 9, Issue 6 Nov - Dec 2024, pp: 684-689 www.ijprajournal.com ISSN: 2456-4494

lead to differences in drug response among patients, highlighting the need for careful monitoring and potential adjustments in dosing. Further research is warranted to explore the long-term impacts of these formulations on clinical outcomes and to investigate patientspecific factors affecting digitoxin metabolism. Overall, ensuring optimal bioavailability is crucial for maximizing the therapeutic benefits of digitoxin in treating cardiovascular condition

REFERNCE

[1]. Chow SC, Liu JP. Design and Analysis of Bioavailability and Bioequivalence Studies. 3. Chapman Hall/CRC Press, Taylor& Francis; New York, New York, USA: 2008. [Google Scholar]

[2]. Balant LP. Is there a need for more precise definitions of bioavailability? European Journal of Clinical Pharmacology. 1991;40:123–126. [PubMed] [Google Scholar

[3]. Purich E. In: Bioavailability/Bioequivalence Regulations: An FDA Perspective in Drug Absorption and Disposition: Statistical Considerations. Albert KS, editor. American Pharmaceutical Association, Academy of Pharmaceutical Sciences; Washington, DC: 1980. pp. 115–137. [Google Scholar]

[4]. FDA. Guidance on Bioavailability and Bioequivalence Studies for Orally Administrated Drug Products – General Considerations. Center for Drug Evaluation and Research, the US Food and Drug Administration; Rockville, Maryland, USA: 2003. [Google Scholar]

[5]. Phillips KF. Power of the two one-sided tests procedure in bioequivalence. Journal of Pharmacokinetics and Biopharmaceutics. 1990;18:137–144. doi: 10.1007/BF01063556. [DOI] [PubMed] [Google Scholar]

[6]. Chen KW, Li G, Chow SC. A note on sample size determination for bioequivalence studies with higher-order crossover designs. Journal of Pharmacokinetics and Biopharmaceutics. 1997;25:753–765. doi: 10.1023/a:1025738019069. [DOI] [PubMed] [Google Scholar

[7]. Hauschke D, Steinijans VW, Diletti E, Durke M. Sample size determination for bioequivalence assessment using a multiplicative model. Journal of Pharmacokinetics and Biopharmaceutics. 1992;20:557–561. doi: 10.1007/BF01061471. [DOI] [PubMed] [Google Scholar]

[8]. Chow SC, Shao J. An alternative approach for the assessment of bioequivalence between two formulations of a drug. Biometrical Journal. 1990;32:969–976. [Google Scholar]

[9]. Chow SC, Shao J, Wang H. Statistical tests for population bioequivalence. Statistica Sinica. 2002;13:539–554. [Google Scholar]

[10]. Chow SC. Individual bioequivalence – a review of the FDA draft guidance. Drug Informational Journal. 1999;33:435–444. [Google Scholar]

[11]. Hyslop T, Hsuan F, Holder KJ. A small-sample confidence interval approach to assess individual bioequivalence. Statistics in Medicine. 2000;19:2885–2897. doi: 10.1002/1097-0258(20001030)19:20<2885::aid-sim553>3.0.co;2-h. [DOI] [PubMed] [Google Scholar]

[12]. Haidar SH, Makhlouf F, Schuirmann DJ, Hyslop T, Davit B, Conner D, Yu LX. Evaluation of a scaling approach for the bioequivalence of highly variable drugs. The AAPS Journal. 2008;10:450–454. doi: 10.1208/s12248-008-9053-4. [DOI] [PMC free article] [PubMed] [Google Scholar]

[13]. Tothfalusi L, Endrenyi L, Arieta AG. Evaluation of bioequivalence for highly variable drugs with scaled average bioequivalence. Clinical Pharmacokinetics. 2009;48:725–743. doi: 10.2165/11318040-000000000-00000. [DOI] [PubMed] [Google Scholar]